Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Centralization of Eliquis Bleeding Cases To Be Considered By MDL Panel December 30, 2016 Austin Kirk Add Your Comments The U.S. Judicial Panel on Multidistrict Litigation has scheduled oral arguments for late next month, to consider whether to centralize and consolidate all Eliquis lawsuits filed by individuals who allege the blood thinner caused them to suffer severe, uncontrollable bleeding problems. In recent months, a growing number of product liability lawsuits have been brought against Bristol-Myers Squibb and Pfizer Inc., alleging that they failed to disclose the risk of bleeding problems associated with their new generation anticoagulant. There are currently at least 34 complaints pending in 13 different U.S. District Courts nationwide, each involving similar claims that the drug makers failed to adequately warn consumers and the medical community about the side effects of Eliquis, and the lack of an effective reversal agent that would allow doctors to stop bleeding that may develop among users. Learn More About Eliquis Lawsuit Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Eliquis Lawsuit Learn More SEE IF YOU QUALIFY FOR COMPENSATION Eliquis is part of a new crop of oral anticoagulants introduced in recent years, known as factor xa medications, which also include the blockbuster treatments Xarelto and Pradaxa. The drugs have been aggressively marketed as a replacement for Coumadin (warfarin), which has been the go-to anticoagulation treatment for decades. However, unlike warfarin, these new drugs had no safe and effective antidote available when they were introduced, and a large number of bleeding problems with Eliquis, Xarelto and Pradaxa have been reported in recent years. Thousands of Xarelto lawsuits and Pradaxa lawsuits have already been filed against the makers of these competing, and more popular, anticoagulants. Separate MDLs, or multidistrict litiations have previously been established by the U.S. JPML for cases involving these other factor xa medication. While a relatively small number of Eliquis cases have been filed to date, it is expected that the number of complaints will continue to increase in the coming weeks and months, likely involving hundreds, or even thousands, of cases involving severe bleeds or wrongful death. In a motion to transfer (PDF) filed with the JPML on October 13, Bristol -Myers Squibb and Pfizer Inc. requested that all Eliquis complaints filed in U.S. District Courts nationwide be consolidated before one judge to prevent duplicative discovery into common issues in the cases, avoid contradictory rulings from different judges, and to serve the convenience of the parties, witnesses and the judicial system. In a hearing order (PDF) issued on December 15, the JPML set oral arguments for January 26, 2017 at the Wilkie D. Ferguson, Jr. United States Courthouse in Miami, Florida. Tags: Bleeding, Blood Thinner, Bristol Myers Squibb, Eliquis, Pfizer, Pradaxa, Warfarin, Xarelto Image Credit: | More Eliquis Lawsuit Stories Eliquis More Effective At Preventing Recurring Blood Clots, Embolism, Than Xarelto: Study December 22, 2021 Eliquis Useful In Preventing Blood Clots, But Side Effects Include Major Bleeding Risks: Study December 26, 2018 FDA Approves AndexXa as Reversal Agent For Xarelto, Eliquis May 7, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Lawsuit Pre-Settlement Funding and Loans Must Be Disclosed Under Court Order (Posted: today) A U.S. District Judge has ordered women involved in Depo-Provera lawsuits to inform him of any third-party pre-settlement loans they take out, as predatory interest rates may force them to reject settlement offers. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (07/02/2025)Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025) Judge Extends Deadlines in PFAS Lawsuits Over Liver Cancer, Thyroid Cancer (Posted: today) A federal judge has extended deadlines for parties involved in firefighting foam lawsuits to complete discovery and expert reports on liver and thyroid cancer injuries. MORE ABOUT: AFFF LAWSUITPFAS Exposure During Pregnancy Linked to High Blood Pressure in Children: Study (06/26/2025)PFAS Drinking Water Lawsuit Filed by 16 Plaintiffs Over Testicular Cancer, Kidney Cancer, Ulcerative Colitis Side Effects (06/23/2025)AFFF Chemicals May Accelerate Spread of Cancer, Reduce Drug Effectiveness: Study (06/13/2025) Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: yesterday) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Eliquis More Effective At Preventing Recurring Blood Clots, Embolism, Than Xarelto: Study December 22, 2021
Eliquis Useful In Preventing Blood Clots, But Side Effects Include Major Bleeding Risks: Study December 26, 2018
Depo-Provera Lawsuit Pre-Settlement Funding and Loans Must Be Disclosed Under Court Order (Posted: today) A U.S. District Judge has ordered women involved in Depo-Provera lawsuits to inform him of any third-party pre-settlement loans they take out, as predatory interest rates may force them to reject settlement offers. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (07/02/2025)Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)
Judge Extends Deadlines in PFAS Lawsuits Over Liver Cancer, Thyroid Cancer (Posted: today) A federal judge has extended deadlines for parties involved in firefighting foam lawsuits to complete discovery and expert reports on liver and thyroid cancer injuries. MORE ABOUT: AFFF LAWSUITPFAS Exposure During Pregnancy Linked to High Blood Pressure in Children: Study (06/26/2025)PFAS Drinking Water Lawsuit Filed by 16 Plaintiffs Over Testicular Cancer, Kidney Cancer, Ulcerative Colitis Side Effects (06/23/2025)AFFF Chemicals May Accelerate Spread of Cancer, Reduce Drug Effectiveness: Study (06/13/2025)
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: yesterday) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)